K13v1NJR
Search
Menu
  • MAIN NJR WEBSITE
  • CLINICIAN FEEDBACK
  • SURGEON AND HOSPITAL PROFILE
  • CONTACT US
NJR NJR
 

Back to Reports List

NJR STRUCTURE & GOVERNANCE

ANNUAL REPORT 2020

Chairman’s Foreword 2020Introduction to Annual Report 2020Executive Summary

WELSH TRANSLATION

WORK - ANNUAL PROGRESS

Data Completeness and QualityWork of the NJR committeesDevelopments

HIPS

All Procedures - ActivityPrimary Procedures - Patient CharacteristicsPrimary Procedures - Surgical TechniquePrimary Procedures - ComponentsRevision Procedures - Patient CharacteristicsRevision Procedures - Components

KNEES

All Procedures - ActivityPrimary Procedures - Patient CharacteristicsPrimary Procedures - Surgical TechniquePrimary Procedures - ComponentsRevision Procedures - Patient Characteristics

ANKLES

All Procedures - ActivityPrimary Procedures - Patient CharacteristicsPrimary Procedures - Surgical TechniquesPrimary Procedures - ComponentsRevision Procedures

ELBOWS

Primary Procedures - ActivityPrimary Procedures - Patient CharacteristicsPrimary Procedures - Surgical TechniquesPrimary Procedures - Elbow ComponentsRevision Procedures

SHOULDERS

Primary Procedures - ActivityPrimary Procedures - Patient CharacteristicsPrimary Procedures - Surgical TechniquePrimary Procedures - Shoulder ComponentsRevision Procedures

ALL JOINTS
 

All Procedures - Activity

HOSPITAL PERFORMANCE

IMPLANT PERFORMANCE

DOWNLOADS

ARCHIVE


16th Annual Report
published Sept 2019

15th Annual Report
published Sept 2018
14th Annual Report
published Sept 2017
13th Annual Report
published Sept 2016
12th Annual Report
published Sept 2015
11th Annual Report
published Sept 2014

Thromboprophylaxis regime for primary knee replacement patients, prescribed at the time of operation

  • SUMMARY
  • CHART AND TABLE

The table shows the chemical and mechanical thromboprophylaxis reported as being prescribed for primary knee replacement patients.  Please note that the reported use of thromboprophylaxis is what is prescribed at the time of the operation and does not include any information about the length of time the thromboprophylaxis was prescribed for.  

Report Viewer Configuration Error

The Report Viewer Web Control HTTP Handler has not been registered in the application's web.config file. Add <add verb="*" path="Reserved.ReportViewerWebControl.axd" type = "Microsoft.Reporting.WebForms.HttpHandler, Microsoft.ReportViewer.WebForms, Version=14.0.0.0, Culture=neutral, PublicKeyToken=89845dcd8080cc91" /> to the system.web/httpHandlers section of the web.config file, or add <add name="ReportViewerWebControlHandler" preCondition="integratedMode" verb="*" path="Reserved.ReportViewerWebControl.axd" type="Microsoft.Reporting.WebForms.HttpHandler, Microsoft.ReportViewer.WebForms, Version=14.0.0.0, Culture=neutral, PublicKeyToken=89845dcd8080cc91" /> to the system.webServer/handlers section for Internet Information Services 7 or later.

Browser not supported

Report Viewer requires a standards compliant browser. Users of Internet Explorer 8 and earlier should switch to a modern browser, or if already using a modern browser target standards mode by adding the <meta http-equiv="X-UA-Compatible" content="IE=edge" > header tag to the host page.

Loading...
Cancel
CSV (comma delimited)
PDF
Excel
Word

Print

Cancel

Done

❌
Thromboprophylaxis regime for primary knee replacement patients in 2019, prescribed at time of operation.
 
Primary total knee replacement
Primary unicondylar
Primary multi-compartmental
Primary patello femoral
Primary total prosthetic replacement not classified elsewhere (e.g. hybrid)
 
Total
 
No.
%
No.
%
No.
%
No.
%
No.
%
No.
%
Total knee primaries
94,516
 
12,517
 
36
 
997
 
440
 
108,506
 
Low molecular weight Heparin
61,966
66%
7,077
57%
15
42%
533
53%
208
47%
69,799
64%
Aspirin
30,120
32%
4,852
39%
16
44%
451
45%
187
43%
35,626
33%
Factor Xa Inhibitor (eg Rivaroxaban/Apixaban)
17,798
19%
2,761
22%
3
8%
143
14%
82
19%
20,787
19%
Pentasaccharide (eg Fondaparinux)
17,302
18%
1,804
14%
10
28%
140
14%
76
17%
19,332
18%
Warfarin
10,057
11%
1,817
15%
8
22%
165
17%
73
17%
12,120
11%
Direct Thrombin Inhibitor (eg Dabigitran)
7,425
8%
911
7%
7
19%
109
11%
9
2%
8,461
8%
Other chemical
22,912
24%
3,895
31%
5
14%
280
28%
164
37%
27,256
25%
No chemical
1,412
1%
166
1%
0
0%
8
1%
4
1%
1,590
1%
TED stockings
72,159
76%
8,775
70%
29
81%
672
67%
265
60%
81,900
75%
Intermittent calf compression
57,584
61%
7,079
57%
25
69%
587
59%
350
80%
65,625
60%
Foot pump
53,314
56%
7,354
59%
25
69%
645
65%
229
52%
61,567
57%
Other mechanical
4,840
5%
450
4%
1
3%
30
3%
14
3%
5,335
5%
No mechanical
5,253
6%
709
6%
3
8%
60
6%
7
2%
6,032
6%
Both mechanical and chemical
89,678
95%
11,784
94%
32
89%
939
94%
432
98%
102,865
95%
Neither mechanical nor chemical
36
<1%
5
<1%
0
0%
0
0%
1
<1%
42
<1%
© National Joint Registry 2020

Reporting Period

Date Range

Data to 31/12/2013

Data to 31/12/2014

Data to 31/12/2015

Data to 31/12/2016

Data to 31/12/2017

Data to 31/12/2018

Data to 31/12/2019

Filter

Calendar Year

2011

2012

2013

2014

2015

2016

2017

2018

2019

Reset filters


Please set a value for all filters.

    © Copyright 2014 NJR